Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 2/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 2/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 2/20 | 1.00 |
| ▸ | DGKA | P23743 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | FAAH | O00519 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
| ▸ | CNR2 | P34972 | 1/20 | 0.68 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | SELP | P16109 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5424593 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL10492134 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL16431952 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL480475 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8384463 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8384469 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL2179183 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8384789 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL21436106 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8750559 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1905 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075739-A | CircRNA-LNP delivery system for in-vivo induction generation of iTreg, and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-120754262-B | Nucleic acid delivery vector and preparation method and application thereof | Shenzhen Jinlin Biotechnology Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-120530909-B | Early breeding and evaluating method for salt tolerance of grass carp based on serum metabolic markers | 中国水产科学研究院淡水渔业研究中心 | 2026-05-19 | — | — | CN | claimed |
| WO-2026098635-A1 | NEW CATIONIC LIPID WITH NITROGEN-CONTAINING HETEROCYCLIC HEAD GROUP AND USE THEREOF | 厦门赛诺邦格生物科技股份有限公司 | 2026-05-15 | — | — | WO | claimed |
| CN-122055141-A | Polyvinylpyrrolidone stabilizer, composition, use and preparation method thereof | 环球生命科学解决方案加拿大有限公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2026098601-A1 | LIPID NANOPARTICLE FOR DELIVERING LOAD | 北京剂泰生命科技有限公司 | 2026-05-15 | — | — | WO | claimed |
| EP-4342929-B1 | POLYETHYLENE GLYCOL LIPID AND USE THEREOF | JENKEM TECH CO LTD TIANJIN (CN) | 2026-02-04 | — | — | EP | claimed |
| US-12508224-B2 | Treating microvascular dysfunction | EndoProtech, Inc. (US) | 2025-12-30 | — | — | US | claimed |
| EP-4667492-A2 | TARGETED LIPID PARTICLES FOR SYSTEMIC DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES | Ramot at Tel-Aviv University Ltd. (IL) | 2025-12-24 | — | — | EP | claimed |
| EP-4647421-A1 | COMPOUND FOR DELIVERING DRUG, AND LIPOSOME AND DRUG CARRIER | Westgene Biopharma Co., Ltd. (CN) | 2025-11-12 | — | — | EP | claimed |
| CN-1160357-A | Gas filled microspheres as computed tomography contrast agents | IMARX PHARMACEUTICAL CORP (US) | 1997-09-24 | — | — | CN | claimed |
| CN-1137748-A | Gas used as local and subcutaneous transmission carrier and microspheres filled with gas precursor | IMARX PHARMACEUTICAL CORP (US) | 1996-12-11 | — | — | CN | claimed |
| EP-0740528-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1996-11-06 | — | — | EP | claimed |
| CN-1125393-A | Novel therapeutic delivery systems | IMARX PHARMACEUTICAL CORP (US) | 1996-06-26 | — | — | CN | claimed |
| WO-1995024184-A1 | GAS FILLED MICROSPHERES AS MAGNETIC RESONANCE IMAGING CONTRAST AGENTS | UNGER EVAN C (US) | 1995-09-14 | — | — | WO | claimed |
| WO-1995015118-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1995-06-08 | — | — | WO | claimed |
| US-5358714-A | Diacylglycerols as chemical activators of protein kinase C enzymes for inducing and increasing hair growth | UNILEVER PATENT HOLDINGS B.V. (NL) | 1994-10-25 | — | — | US | claimed |
| EP-0334585-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1994-09-14 | — | — | EP | claimed |
| EP-0489581-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1992-06-10 | — | — | EP | claimed |
| EP-0334585-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1989-09-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508224-B2 | Treating microvascular dysfunction | LPL, PNLIP, LIPG | PRKCA 871/4885PRKCE 798/4885PRKCQ 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.